參考文獻 |
1.National Asthma Education and Prevention Program (National
Heart Lung and Blood Institute). Expert Panel Report 3:
Guidelines for the Diagnosis and Management of Asthma:
Full Report 2007. U.S. Department of Health and Human
Services, National Institutes of Health, National Heart,
Lung, and Blood Institute.
2.Global Initiative for Asthma (GINA). Global Strategy for
Asthma Management and Prevention(Updated 2012).
3.Jan IS, Chou WH, Wang JD, Kuo SH. Prevalence of and major
risk factors for adult bronchial asthma in Taipei city. J
Formos Med Assoc 2004; 103: p.259-63.
4.Wu WF, Wan KS, Wang SJ, Yang W, Liu WL. Prevalence,
severity, and time trends of allergic conditions in 6-to-7-
year-old schoolchildren in Taipei. J Investig Allergol
Clin Immunol 2011; 21(7): p.556-62.
5.Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K.
Cancer risk in hospitalised asthma patients. Br J Cancer
2009; 100: p.829–33.
6.Hwang CY, Chen YJ, Lin MW, Chen TJ, Chu SY, Chen CC, Lee
DD, Chang YT, Wang WJ, Liu HN. Cancer risk in patients
with allergic rhinitis, asthma and atopic dermatitis: a
nationwide cohort study in Taiwan. Int J Cancer 2012;
130(5): p.1160–7.
7.Lisa M. Coussens, Zena Werb. Inflammation and cancer.
Nature 2002; 420: p.860-867.
8.Alberto Mantovani, Paola Allavena, Antonio Sica, Frances
Balkwill. Cancer-related inflammation. Nature 2008; 454:
p.436–444.
9.van den Berge M, ten Hacken NH, Kerstjens HAM, Postma DS.
Management of asthma with ICS and LABAs: different
treatment strategies. Clin Med Ther 2009; 1: p.77-93.
10.Sadatsafavi M, Lynd L, Marra C, Bedouch P, Fitzgerald M.
Comparative outcomes of leukotriene receptor antagonists
and long-acting beta-agonists as add-on therapy in
asthmatic patients: a population-based study. J Allergy
Clin Immunol 2013; 132: p.63-9.
11.Tee AK, Koh MS, Gibson PG, et al. Long-acting beta2-
agonists versus theophylline for maintenance treatment of
asthma. Cochrane Database Syst Rev 2007; 18(3):CD001281.
12.Hsiao JL, Chen FS, Wang YL, Chen CY. The prescription
trend analysis of the use of inhalers in Taiwanese
asthmatics. Formosa Journal of Clinical Pharmacy 2012;
20(2): p.141-155.
13.Nargues A. Weir, Stewart J. Levine. Achieving symptom
control in patients with moderate asthma. Clinical
Medicine Insights: Circulatory, Respiratory and Pulmonary
Medicine 2012; 6: p.1-11.
14.Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au
DH. Inhaled corticosteroids and risk of lung cancer among
patients with COPD. Am J Respir Crit Care Med 2007; 175:
p.712-719.
15.Victor A. Kiri, Leonardo M. Fabbri, Kourtney J. Davis,
Joan B. Soriano. Inhaled corticosteroids and risk of lung
cancer among COPD patients who quit smoking. Respiratory
Medicine 2009; 103: p.85-90.
16.Lee CH, Hyun MK, Jang EJ, Lee NR, Kim K, Yim JJ. Inhaled
corticosteroid useand risks of lung cancer and laryngeal
cancer. Respir Med 2013; 107: p.1222-33.
17.Dietrich K, Schned A, Fortuny J, et al. Glucocorticoid
therapy and risk of bladder cancer. Br J Cancer 2009;
101: p.1316–20.
18.Severi G, Baglietto L, Muller DC, et al. Asthma, asthma
medications, and prostate cancer risk. Cancer Epidemiol
Biomarkers Prev 2010; 19: p.2318–24.
19.Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer
SK, Nierenberg DW. Non-melanoma skin cancers and
glucocorticoid therapy. Br J Cancer 2001; 85: p.683–6.
20.Sorensen GV, Cronin-Fenton DP, Sorensen HT, Ulrichsen SP,
Pedersen L, Lash TL. Use of glucocorticoids and risk of
breast cancer: a Danish population-based case-control
study. Breast Cancer Res 2012; 14: R21.
21.Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM.
The Salmeterol Multicenter Asthma Research Trial: a
comparison of usual pharmacotherapy for asthma or usual
pharmacotherapy plus salmeterol. Chest 2006; 129:
p.15–26.
22.Drazen JM, O’Byrne PM. Risks of long-acting
beta-agonists in achieving asthma control. N Engl J Med
2009; 360: p.1671-2.
23.Chowdhury BA, Dal Pan G. The FDA and safe use of
long-acting beta-agonists in the treatment of asthma. N
Engl J Med 2010; 362: p.1169-71.
24.Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason-
Comstock J, Williams LK. The relationship between
combination inhaled corticosteroid and long-acting
beta-agonist use and severe asthma exacerbations in a
diverse population. J Allergy Clin Immunol 2012; 129:
p.1274–1279.
25.Ducharme FM, Chronin N, Greenstone I, Lasserson TJ.
Addition of long-acting beta2-agonists to inhaled
steroids versus higher dose inhaled steroids in adults
and children with persistent asthma. Cochrane Database
Syst Rev 2010; (4):CD005533
26.Kelly HW. Comparison of inhaled corticosteroids. Ann
Pharmacother 1998; 32: p.220-232.
27.Walser T, Cui X, Yanagawa J, et al. Smoking and lung
cancer: the role of inflammation. Proc Am Thorac Soc
2008; 5(8): p.811–815.
28.Yasushi Rino, Kazuo Tarao. Anti-Inflammatory Drugs Reduce
the Risk of Hepatocellular Carcinoma Development. ISRN
Oncology 2011; 2011.
29.Sahasrabuddhe V V, Gunja MZ, Graubard BI, Trabert B,
Schwartz LM, Park Y, et al. Nonsteroidal
anti-inflammatory drug use, chronic liver disease, and
hepatocellular carcinoma. J Natl Cancer Inst 2012; 104:
p.1808-1814.
30.Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM,
Nelson WG. Anti-inflammatory drugs, antioxidants, and
prostate cancer prevention. Curr Opin Pharmacol 2009; 9:
p.419–26.
31.Mahmud SM, Franco EL, Turner D et al. Use of
non-steroidal anti-inflammatory drugs and prostate cancer
risk: a population-based nested case-control study. PLoS
One 2011; 6(1): e16412.
32.Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of
aspirin, but not other non-steroidal anti-inflammatory
drugs is associated with decreased prostate cancer risk
at the population level. Eur J Cancer 2013; 49: p.938-945.
33.Spies CM, Strehl C, van der Goes MC, Bijlsma JW,
Buttgereit F. Glucocorticoids. Best Pract Res Clin
Rheumatol 2011; 25: p.891-900.
34.Jensen P, Hansen S, Möller B et al. Skin cancer in kidney
and heart transplant recipients and different long-term
immunosuppressive therapy regimens. J Am Acad Dermatol
1999; 40: p.177–86.
35.De Hertog SA, Wensveen CA, Bastiaens MT, et al. Relation
between smoking and skin cancer. J Clin Oncol 2001; 19:
p.231-8.
36.Rollison DE, Iannacone MR, Messina JL, Glass LF, Giuliano
AR, Roetzheim RG, et al. Case-control study of smoking
and non-melanoma skin cancer. Cancer Causes Control 2012;
23: p.245-54.
37.P. A. Jayalekshmi, P. Gangadharan, S. Akiba, R. R. K.
Nair, M. Tsuji, and B. Rajan. Tobacco chewing and female
oral cavity cancer risk in Karunagappally cohort, India.
The British Journal of Cancer 2009; 100(5): p.848–852.
38.SV Glavey, N Keane, M Power, AW O′Regan. Posterior
Pharyngeal Candidiasis in the Absence of Clinically Overt
Oral Involvement: A Cross-Sectional Study. Lung 2013;
191(6): p.663-668.
39.Sanjaya PR, Gokul S, Gururaj PB, Raju R. Candida in oral
pre-cancer and oral cancer. Med Hypotheses 2011; 77:
p.1125–1128.
40.Dahl R. Systemic side effects of inhaled corticosteroids
in patients with asthma. Respir Med 2006; 100(8):
p.1307-17. |